| Dr Laurie Ann Duckett, DO | |
|
1809 E 13th St Ste 400, Tulsa, OK 74104-4431 | |
| (918) 599-8200 | |
| (918) 579-2559 |
| Full Name | Dr Laurie Ann Duckett |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 35 Years |
| Location | 1809 E 13th St Ste 400, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114923794 | NPI | - | NPPES |
| 100136020B | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0122X | Surgery - Plastic And Reconstructive Surgery | 2860 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Oklahoma State University Medical Center | Tulsa, OK | Hospital |
| Saint Francis Hospital, Inc | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Osumc Professional Services Llc | 9234254012 | 27 |
News Archive
Envoy Therapeutics, a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck.
Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company's Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) ("PFS"). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company's PFS in their generic category.
Centinel Spine, Inc., the pioneer of spinal Stand-Alone, No-Profile®, Integrated Interbody™ devices has now implanted 20,000 STALIF C cervical Integrated Interbody devices. The STALF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.
› Verified 7 days ago
| Entity Name | Ahs Oklahoma Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235182775 PECOS PAC ID: 9436122496 Enrollment ID: O20040817001197 |
News Archive
Envoy Therapeutics, a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck.
Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company's Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) ("PFS"). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company's PFS in their generic category.
Centinel Spine, Inc., the pioneer of spinal Stand-Alone, No-Profile®, Integrated Interbody™ devices has now implanted 20,000 STALIF C cervical Integrated Interbody devices. The STALF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.
› Verified 7 days ago
| Entity Name | Osumc Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922325992 PECOS PAC ID: 9234254012 Enrollment ID: O20100916000969 |
News Archive
Envoy Therapeutics, a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck.
Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company's Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) ("PFS"). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company's PFS in their generic category.
Centinel Spine, Inc., the pioneer of spinal Stand-Alone, No-Profile®, Integrated Interbody™ devices has now implanted 20,000 STALIF C cervical Integrated Interbody devices. The STALF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.
› Verified 7 days ago
| Entity Name | Oklahoma State University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700994878 PECOS PAC ID: 2769739358 Enrollment ID: O20180730000192 |
News Archive
Envoy Therapeutics, a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck.
Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company's Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) ("PFS"). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company's PFS in their generic category.
Centinel Spine, Inc., the pioneer of spinal Stand-Alone, No-Profile®, Integrated Interbody™ devices has now implanted 20,000 STALIF C cervical Integrated Interbody devices. The STALF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laurie Ann Duckett, DO 1809 E 13th St Ste 400, Tulsa, OK 74104-4431 Ph: (918) 599-8200 | Dr Laurie Ann Duckett, DO 1809 E 13th St Ste 400, Tulsa, OK 74104-4431 Ph: (918) 599-8200 |
News Archive
Envoy Therapeutics, a drug discovery company, today announced that it has reached a milestone in its strategic alliance with Merck.
Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company's Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) ("PFS"). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company's PFS in their generic category.
Centinel Spine, Inc., the pioneer of spinal Stand-Alone, No-Profile®, Integrated Interbody™ devices has now implanted 20,000 STALIF C cervical Integrated Interbody devices. The STALF C device is implanted during cervical fusion procedures to treat degenerative spinal disorders.
Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, announced today that its Symphony™ tCGM System has been featured in a March 31, 2010 online magazine article in Scientific American entitled "This Really Won't Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings," by Larry Greenemeier.
Researchers reported on a study of a new oral anti-clotting agent - rivaroxaban - designed to identify doses that would be safe to test in subsequent Phase III efficacy and safety trials. The results of ATLAS ACS-TIMI 46 were presented as a late-breaking clinical trial at the American Heart Association's Scientific Sessions 2008.
› Verified 7 days ago
Alex Bryan Olsen, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 6161 S Yale Ave, Tulsa, OK 74136 Phone: 918-494-1805 Fax: 918-494-4573 | |
Shelley Capehart, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 6465 S Yale Ave, Suite 900, Tulsa, OK 74136 Phone: 918-481-4800 Fax: 918-481-4826 | |
Charles Anthony Howard, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1919 S Wheeling Ave, Suite 600, Tulsa, OK 74104 Phone: 918-744-3523 Fax: 918-744-3463 | |
Wyatt Ho, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 6465 S Yale Ave, Suite 101, Tulsa, OK 74136 Phone: 918-502-7175 Fax: 918-502-7180 | |
Peter Richard Nelson, MD, MS Surgery Medicare: Accepting Medicare Assignments Practice Location: 1919 S Wheeling Ave Ste 600, Tulsa, OK 74104 Phone: 918-619-4400 Fax: 918-634-7560 | |
Scott A Newbrough, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2000 S Wheeling Ave Ste 100, Tulsa, OK 74104 Phone: 918-403-7070 Fax: 918-403-6327 | |
Dr. Susan A Rose, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1725 E 19th St, Suite 800, Tulsa, OK 74104 Phone: 918-301-2505 Fax: 918-301-3633 |